NCT07513285

ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2026-09-25Est. Completion: 2027-09-29

Enrollment target: 20 participants

Locations

UC Davis Medical Center, Sacramento, California, United States
Gastroenterolgy Center of Conneticut, Hamden, Connecticut, United States
Florida International Medical Research, Coral Gables, Florida, United States
L&A Morales Healthcare, Inc, Hialeah, Florida, United States
San Marcus Research Clinc, Inc, Miami Lakes, Florida, United States
Belis Delgado, MD PA, Miami Springs, Florida, United States
Infectious Disease Consultants of Georgia, Athens, Georgia, United States
Snake River Research PLLC, Idaho Falls, Idaho, United States
Endevour Health, Skokie, Illinois, United States
Newton-Wellesley Hospital, Newton, Massachusetts, United States
University of Massachusetts Memorial Healthcare, Worcester, Massachusetts, United States
Henry Ford Hospital, Detroit, Michigan, United States
University of Minnesota, Minneapolis, Minnesota, United States
DiGiovanna Institute for Medical Education and Research, Massapequa, New York, United States
Gastroenterology Associates of the Piedmont, PA, Winston-Salem, North Carolina, United States

Clostridium Difficile Infection

This is a Phase 1, first-in-human, double-blind, placebo-controlled, adaptive-design, single-site study, involving dose …

Knoxville, United StatesEst. completion Aug 22, 2028

Enterobacteriaceae InfectionsCarbapenem-Resistant Enterobacteriaceae InfectionImmunocompromised HostDrug Resistance, Multiple, Bacterial

The goal of this observational study is to learn about the effectiveness and safety of aztreonam-avibactam, an antibioti…

Buenos Aires, ArgentinaEst. completion Nov 1, 2028

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.